title: Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies.
abstract: Chemotherapies drugs and monoclonal antibodies are key components of the treatment of cancer patients and patients with chronic inflammatory conditions to provide increase in life expectancy and quality of life. Their increased use has lead to an increase in drugs hypersensitivity reactions (DHR) worldwide. DHR to those agents prevented their use and promoted the use of second line therapies to protect patients' hypersensitive reactions and anaphylaxis. Second line medications may not fully address the patients' medical condition and it is desirable to keep patients on first line therapy. Drug hypersensitivity symptoms can range from mild cutaneous reactions to life-threatening anaphylaxis. Rapid drug desensitization (RDD) is a novel approach to the management of drug hypersensitivity reactions which are IgE and non-IgE mediated. Through the diferent desensitization protocols patients can receive the full dose of the medications that they have presented a hypersensitive reaction and been protected against anaphylaxis. This review looks at the current literature on hypersensitivity reactions (HSR) to chemotherapy drugs and monoclonal antibodies and the potential use of RDD for their management.
authors: Rafael
authors: R
authors: Bonamichi-Santos
authors: Division of Rheumatology, Immunology and Allergy; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
authors: Mariana
authors: M
authors: Castells
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000276:immunology* / Q000627:therapeutic use*; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological
keywords: Adverse drug reaction.; Chemotherapy; Drug hypersensitivity reaction; Monoclonal antibodies; Rapid drug desensitization